The last 10 years have seen a rev o lu tion in drug de vel op ment. Time lines have short ened, par tic u lar ly in on col o gy. Reg u la tors have opened up. In vest ment has sky rock et ed. Chi na be came a play er. Biotechs have mul ti plied as gene and cell ther a py has ex plod ed — of fer ing ma jor new ad vances in the way dis eases are treat ed, and some times cured.
Image: llogene HQ Open House on September 17, 2019 in South San Francisco. (Jeff Rumans, Endpoints News)
A team of researchers has published evidence showing in mice that mitochondria-associated pathways in cell bodies and dendrites within the CA2 subregion of the brain’s hippocampus influence plasticity and mitochondrial respiration—a finding that highlights a potential molecular target for treating human neurodegenerative disorders ranging from autism to Alzheimer’s disease.
Image: Shannon Farris, PhD, a principal investigator at the Center for Neurobiology Research, Fralin Biomedical Research Institute at Virginia Tech Carilion
Thanks to a yearslong boom in the world of venture capital, keeping tabs on biotech means constantly reading that some so-called startup is suddenly worth more than $1 billion. But just who is putting the horns on all these unicorns?
Welcome back to “The Facts, STAT!”, a not-infrequent STAT video series in which our reporters briefly explain the need-to-know basics of issues in the world of health care and biotech.
Image: https://www.statnews.com – From Video
Venture capitalists are pouring cash into U.S. biotechs at a rate set to replicate 2018’s record deal count, according to PitchBook and the National Venture Capital Association’s third-quarter Venture Monitor report.
In the first three quarters alone, VCs struck 609 biopharma deals — the majority of which were Series A or B — and contributed $11.5 billion in investments.
Notably, the average deal size shrunk from a 2018 high of $25.6 million to $21.2 million. That figure reflects growth in early stage investments but significant declines in late stage.
The number of investments that venture capitalists will make this year in pharmaceutical and biotech companies is on pace to match last year’s record—and that money continues to shift into earlier-stage deals.
Venture firms invested in 609 drug development deals as of Sept. 30, 2019, compared with 808 deals for all last year, according to the latest data from firms that track VC investments.
Since 2016, more than half of the money invested in pharma and biotech each year has been in the riskier angel, seed, Series A, and Series B stages, according to the latest Venture Monitor, a quarterly report published by Pitchbook and the National Venture Capital Association.
Alexandria Real Estate Equities, Inc (ARE) is committed to the Maryland I-270 Corridor market, and is a local partner and advocate for the biotech community. Alexandria provides room to grow through all stages of your company
Our vision at Johnson & Johnson is for every person to use their unique experiences and backgrounds together – to spark solutions that create a better, healthier world.
By seeking out and encouraging diverse ideas and promoting collaborative thinking among inclusive teams, we believe the world can bring innovative healthcare solutions to patients and consumers that will improve health for humanity.
Thank you BioHealth Innovation, Inc. and AstraZeneca for another successful hashtag#BioHealth Capital Region BioBowl last night. The Children’s National Hospital team had a blast. And, we loved the slogan on our T-Shirts “Advancing Science. Accelerating Innovation.”
Richard Bendis Judy Costello @Albine Martin, Ph.D. Luis Gutierrez Jeff Walpole Sara Alyamani Whitney Black, MHA Justin Opfermann Lisa Romano BioBuzz Gayatri Varma Jarrod Borkat TEDCO Arti Santhanam Anthony Ho
hashtag#innovate4kids hashtag#bhcr hashtag#jlabs hashtag#pediatrics hashtag#healthcareinnovation hashtag#innovators
Very cool seeing so many people from the different BioHealth Capital Region. 30+ lanes of companies. BioHealth Innovation, Inc. BioBuzz
It’s getting competitive over here at the amazing hashtag#biobowl19 we are cohosting with AstraZeneca for the BioHealth Capital Region
New Enterprise Associates Partner, Sara Nayeem, M.D., Joins Host Rich Bendis to Discuss Her Career, Venture Capital, and BioPharma
Sara Nayeem, M.D., is a Partner at New Enterprise Associates (NEA). Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Centrexion, Complexa, Cydan, Imara, and Tiburio. She previously served on the boards of Vtesse (acquired by Sucampo), Mersana (MRSN) and Therachon and as a board observer for Loxo Oncology (LOXO, acquired by Lilly), Tesaro (TSRO, acquired by GlaxoSmithKline), Clementia (CMTA, acquired by Ipsen), Nightstar (NITE, acquired by Biogen), Ziarco (acquired by Novartis), Omthera (OMTH, acquired by AstraZeneca), Epizyme (EPZM), Millendo (MLND) and Zyngenia. She has also been involved in other NEA investments such as Prosensa (RNA, acquired by BioMarin), Metacrine, and 3-V Biosciences. She also serves on the board of BioHealth Innovation Management. Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.
Listen now on iTunes (https://apple.co/2o1V6Il), Google Podcasts (http://bit.ly/2oGqQ6h), and TuneIn (http://bit.ly/2ndZGmO).
GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 million in proceeds. Investors include Alexandria Venture Investments as well as a large integrated healthcare delivery network currently exploring the option to implement PhageBank™ therapy within its network of more than 17 hospitals and a NYSE-listed specialty life sciences company. Proceeds will be deployed to support multi-center phase 2 clinical studies for its PhageBank® therapy for antibiotic resistant bacterial infections.
Image: https://biobuzz.io
